Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...

On the efficacy issue, Merck told the meeting ... a temporary EUA until another oral antiviral candidate becomes available. The lack of data for the drug against the emerging Omicron variant ...

Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...

Merck CEO Rob Davis told CNBC's Jim Cramer that there's more to the pharmaceutical giant than its lucrative cancer drug, Keytruda, and he described other ventures in its portfolio. "Keytruda has ...

Morgan Stanley analyst Terence Flynn has maintained their neutral stance on MRK stock, giving a Hold rating yesterday.Invest with Confidence: ...

Merck said it expected sales of $64.1 billion to $65.5 billion in 2025 and adjusted earnings of $8.88 to $9.03 a share. Both forecasts came in below the average analyst expectation for revenue of ...